Immunosuppression Drugs Exhibit Differential Effects on Endothelial Cell Function

Abstract Introduction: Immunosuppressive medications are widely used to treat patients with neoplasms, autoimmune conditions, and solid organ transplants. Prior studies indicate that immunosuppression drugs can cause adverse vascular remodeling. Given the systemic effects of the drugs, elucidating cell-type-specific drug effects has been challenging. Methods: We utilized induced pluripotent stem cell-derived endothelial cells to investigate the role of widely used immunosuppression drugs on endothelial cell function. Results: We found that among immunosuppression agents, sirolimus reduced basic endothelial cell functions including cell migration, proliferation, acetylated LDL uptake, mitochondrial respiration, and angiogenic properties, while tacrolimus only reduced nitric oxide release. Conclusions: This model allows for investigation of differential effect of immunosuppression drugs on endothelial function that can elucidate the mechanisms contributing to clinically observed adverse vascular profiles.

• Publication year

  2025

• Venue

  Journal of Vascular Research

• Publication date

  2025-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000548353PMID 40934129PMCID 12772628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular effects of immunosuppression agents

  2022cited by this paper
• Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy

  2020cited by this paper
• Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay”

  2020cited by this paper
• Effects of Immunosuppressive Medications on Mitochondrial Function.

  2020cited by this paper
• Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome

  2020cited by this paper
• A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation.

  2020influential reference
• Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial

  2019cited by this paper
• Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells

  2017cited by this paper
• Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells

  2016cited by this paper
• Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-κB/LOX-1 Pathway

  2016cited by this paper
• mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.

  2014cited by this paper
• Endothelial cell tube formation assay for the in vitro study of angiogenesis.

  2014cited by this paper
• Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin–angiotensin system

  2014cited by this paper
• Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation

  2014cited by this paper
• Incidence and treatment of lymphedema in heart transplant patients treated with everolimus.

  2014cited by this paper
• Mitochondria, endothelial cell function, and vascular diseases

  2014cited by this paper
• Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide.

  2013cited by this paper
• The role of nitric oxide on endothelial function.

  2012cited by this paper
• Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation.

  2012cited by this paper
• Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.

  2012cited by this paper
• In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: a cross-sectional study.

  2011cited by this paper
• Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes.

  2011cited by this paper
• Cyclosporine A-induced nitration of tyrosine 34 MnSOD in endothelial cells: role of mitochondrial superoxide.

  2010cited by this paper
• Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

  2008cited by this paper
• Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation.

  2008cited by this paper
• Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia.

  2008cited by this paper
• Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma.

  2008cited by this paper
• Removal of Fkbp12/12.6 From Endothelial Ryanodine Receptors Leads to an Intracellular Calcium Leak and Endothelial Dysfunction

  2007cited by this paper
• Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction.

  2007cited by this paper
• Endothelial Mitochondria: Contributing to Vascular Function and Disease

  2007cited by this paper
• In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

  2007cited by this paper
• Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.

  2007cited by this paper
• Faculty Opinions recommendation of The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity.

  2006cited by this paper
• Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial Cells

  2006cited by this paper
• New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?

  2006cited by this paper
• The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity*

  2006cited by this paper
• Effect of calcineurin inhibitors on low-density lipoprotein oxidation.

  2005cited by this paper
• The role of endothelin in FK506-induced vascular reactivity changes in rat perfused kidney.

  2005cited by this paper
• The Impact of Immunosuppression on Endothelial Function

  2005cited by this paper
• Cardiac allograft vasculopathy after heart transplantation: risk factors and management.

  2004cited by this paper
• Dyslipidemia during sirolimus therapy in patients after liver transplantation

  2004cited by this paper
• Allograft-induced proliferation of vascular smooth muscle cells: potential targets for treating transplant vasculopathy.

  2003cited by this paper
• Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria

  2003cited by this paper
• Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

  2003cited by this paper
• Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

  2003cited by this paper
• Cardiovascular Toxicities of Immunosuppressive Agents

  2002cited by this paper
• Posttransplantation hypertension related to calcineurin inhibitors

  2000cited by this paper
• A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.

  1999cited by this paper
• Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin).

  1998cited by this paper
• The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal.

  1997cited by this paper
• The risk of coronary artery disease after heart transplantation is increased in patients receiving low‐dose cyclosporine, regardless of blood cyclosporine levels

  1997cited by this paper
• Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient.

  1997cited by this paper
• Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.

  1995cited by this paper
• Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.

  1995cited by this paper
• Cyclosporine produces endothelial dysfunction by increased production of superoxide.

  1994cited by this paper
• Cyclosporine-induced endothelialitis and accelerated arteriosclerosis in chronic allograft rejection.

  1992cited by this paper
• Chronic rejection of rat aortic allograft: II. Administration of cyclosporin induces accelerated allograft arteriosclerosis

  1991cited by this paper

• No citing papers are available for this paper.